Research programme: siRNA therapeutics - Biocon/Quark Pharmaceuticals
Alternative Names: QP LI1Latest Information Update: 28 Nov 2021
Price :
$50 *
At a glance
- Originator Biocon; Quark Pharmaceuticals
- Class Small interfering RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Lung transplant rejection
Most Recent Events
- 28 Nov 2021 No recent reports of development identified for preclinical development in Lung-transplant-rejection in USA (Inhalation)
- 18 Dec 2013 Investigation in Undefined indication in USA (unspecified route)